Page 155 - 80_01

REVISIÓN

Dry
eye
disease
compounds
currently
under
evaluation
in

clinical
trials

Basilio
Colligris,
Jesús
Pintor*

Departamento
de
Bioquímica
y
Biología
Molecular
IV,
Facultad
de
Óptica
y
Optometría,
Universidad

Complutense
de
Madrid,
Madrid,
España.

*e-­-mail:
jpintor@vet.ucm.es

An.
Real
Acad.
Farm.
Vol
80,
Nº
1(2014),
pág.
151-­-178

ABSTRACT

Dry
eye
syndrome
is
a
common
disorder
provoking
changes
in
tear
quantity
and

composition
being
the
most
common
ophthalmic
manifestation
of
systemic

inflammatory
diseases.
Untreated
dry
eye
could
cause
increased
risk
of
ocular

infection,
corneal
ulcer
and
blindness.
Only
a
few
drugs
are
authorized
so
far
for

the
treatment
of
dry
eye
disease
and
the
possibilities
of
evolution
in
this
sector

are
immense.
Accordingly,
the
future
tendency
is
towards
the
development
of

drugs
to
control
the
inflammation
or
stimulate
the
mucin
and
tear
secretion.
A

significant
number
of
new
potential
solutions
are
under
development
or
placed
in

the
pharmaceutical
pipeline,
promising
better
results
and
lesser
side
effects,
but

still
leaving
unattended
the
main
causes
of
the
disease.
In
this
article,
we
review

the
corresponding
literature,
recent
clinical
trials
data
and
patents
concerning

future
pharmaceutical
compounds
for
dry
eye
disease
treatment,
presenting
the

new
strategic
movements
of
the
pharmaceutical
industry.

Keywords:
Dry
eye;
anti-­-inflammatory;
keratoconjunctivitis
sicca;
keratitis
sicca;

xerophthalmia;
mucin
secretion;
tear
secretion;
NSAID.

151